Propranolol Hydrochloride + Flunarizine HydrochlorideThird Party Manufacturing in India

Propranolol Hydrochloride + Flunarizine Hydrochloride combines a non-selective beta-adrenergic receptor blocker with a selective calcium channel blocker to provide a multi-target approach for migraine prophylaxis and vestibular disorders. Propranolol Hydrochloride is a lipophilic, non-selective beta-blocker that competitively antagonizes beta-1 and beta-2 adrenergic receptors throughout the body. In migraine prophylaxis, its mechanism is multifactorial: it blocks beta-receptors in the vasomotor centre of the brainstem, reducing sympathetic outflow; it inhibits renin release from the kidneys; it decreases cardiac output and reduces cerebral arterial pulsation amplitude; and it modulates serotonin receptor activity in the central nervous system. The sustained-release formulation provides stable plasma levels over 24 hours, optimizing prophylactic efficacy. Flunarizine Hydrochloride is a selective calcium entry blocker belonging to the diphenylalkylamine class. It crosses the blood-brain barrier and selectively inhibits calcium influx into vascular smooth muscle cells and neurons by binding to T-type calcium channels. This prevents cerebral vasoconstriction and reduces cortical spreading depression, the electrophysiological phenomenon believed to underlie migraine aura. Flunarizine also has H₁ antihistamine and dopaminergic antagonist properties that contribute to its anti-migraine and anti-vertigo effects. The combination addresses both vascular and neurological pathways in migraine pathophysiology.

Therapeutic Uses

Propranolol Hydrochloride + Flunarizine Hydrochloride is prescribed for the treatment of:

• Migraine Prophylaxis: Reduces the frequency, duration, and severity of migraine attacks in patients experiencing 4 or more migraines per month. The combination addresses both vascular and neurological components of migraine pathophysiology.
• Vestibular Migraine: Particularly effective for migraine-associated vertigo where both beta-blockade and calcium channel inhibition provide symptom control.
• Chronic Daily Headache: Used in patients with medication-overuse headache and transformed migraine patterns.
• Benign Paroxysmal Positional Vertigo (BPPV): Flunarizine component helps manage vestibular symptoms, while Propranolol addresses the migraine component.
• Cluster Headache Prophylaxis: Adjunctive therapy in selected patients with chronic cluster headache patterns.

Why Manufacturers Choose Propranolol Hydrochloride + Flunarizine Hydrochloride

This fixed-dose combination serves the growing migraine prophylaxis market in India, where migraine prevalence is estimated at 15-20% of the adult population and awareness of prophylactic treatment is increasing. The sustained-release Propranolol technology requires expertise in SR pellet formulation, which establishes a manufacturing capability moat. The combination addresses a specific clinical niche that few fixed-dose combinations target, allowing manufacturers to differentiate their portfolio. Both molecules have well-established, cost-effective API supply chains from domestic Indian manufacturers. The product is particularly popular in neurology specialty practices and is increasingly prescribed by general practitioners as awareness of migraine prophylaxis grows. Indian WHO-GMP certified manufacturers can serve both the domestic PCD franchise market and the growing export demand from Southeast Asian and African markets where migraine care is expanding. This makes Propranolol + Flunarizine one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.